Effects of preovulatory tamoxifen in regularly cycling women on folliculogenesis, oocyte recovery and luteal function.
Forty women undergoing elective sterilization and oocyte donation were randomized in a trial to study the effects of administration of 30 mg of tamoxifen 12 h before injection of human chorionic gonadotrophin and 48 h before oocyte capture. Cycles were regulated for advanced operative scheduling with norethisterone given in the luteal phase of the previous cycle and 150 mg of clomiphene given in the early follicular phase of the recovery cycle. Tamoxifen cycles showed a delay of peak urinary oestrone excretion by 2 days, associated with a slight decrease in total excretion. Tamoxifen administration lengthened treatment cycles by 0.5 days and the luteal phase by 0.4 days. The urinary excretion peak of pregnanediol was 3 days later than in controls. Total pregnanediol excretion was slightly elevated. There were no differences in oocyte recovery rate although cleavage rate was decreased (0.84 versus 0.65, not significant at P greater than or equal to 0.05). Intrafollicular oestradiol levels were similar (794 +/- 97 versus 735 +/- 102 ng/ml). Intrafollicular progesterone levels were marginally lower in tamoxifen cycles (3.5 +/- 0.5 versus 2.3 +/- 0.8 micrograms/ml).
Thatcher
S S
SS
Department of Obstetrics and Gynaecology, University of Edinburgh, UK.
Angell
R E
RE
West
J D
JD
Glasier
A F
AF
Kelly
R W
RW
Hillier
S G
SG
Baird
D T
DT
D000328:Adult; D003338:Corpus Luteum / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008183:Luteal Phase / Q000187:drug effects*; D009865:Oocytes / Q000187:drug effects*; D006080:Ovarian Follicle / Q000187:drug effects* / Q000502:physiology; D013629:Tamoxifen / Q000494:pharmacology*
D013629:Tamoxifen